Premium
TAC urges NIMH to prioritize treatment for schizophrenia
Author(s) -
Canady Valerie A.
Publication year - 2019
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.31742
Subject(s) - schizophrenia (object oriented programming) , psychiatry , clozapine , psychology , schizophrenia research , medicine , psychotherapist
Since clozapine (Clozaril) was approved nearly 30 years ago, there has been no significant pharmacologic advance for schizophrenia, contend Treatment Advocacy Center (TAC) psychiatric researchers in a new article published in the Journal of Clinical Psychiatry . Schizophrenia, they say, is one of the most important diseases in the United States, both socially and economically.